English
Arabic
Chinese (Simplified)
Dutch
Esperanto
French
German
Greek
Italian
Japanese
Korean
Portuguese
Russian
Spanish
UrduIn July, the first direct-to-consumer blood test designed to assess a user’s risk for developing Alzheimer’s disease hit the market.
Tag: Jona Goldrich Center for Alzheimer’s and Memory Disorders
Cedars-Sinai Experts Discuss Pros, Cons of New Alzheimer’s Drug
Cedars-Sinai patient care teams are preparing to offer lecanemab, a new Alzheimer’s disease treatment expected to soon receive approval from the U.S. Food and Drug Administration (FDA), to patients in the coming months.